NMT Medical release positive data from Biostar trial

By Elaine Rigoli

Tampa, Fla., May 16 - NMT Medical, Inc. released the preliminary clinical results from its BEST (bioSTAR evaluation study) trial to evaluate NMT's new bioabsorbable septal closure technology in subjects with patent foramen ovale or atrial septal defect.

At the six-month follow-up period of 57 patients enrolled in the study, data show that at 30 days post-implant with BioSTAR, a complete closure rate was achieved in 88.5% of the study subjects.

At six months, the complete closure rate increased to 96.4%.

NMT Medical develops implant technologies that allow interventional cardiologists to treat cardiac sources of migraine headaches, stroke and other potential brain attacks through minimally invasive, catheter-based procedures.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.